ES2583602T3 - Mezcla de hidratos de carbono y su utilización para preparar un producto destinado a la alimentación oral o enteral - Google Patents
Mezcla de hidratos de carbono y su utilización para preparar un producto destinado a la alimentación oral o enteral Download PDFInfo
- Publication number
- ES2583602T3 ES2583602T3 ES08761564.7T ES08761564T ES2583602T3 ES 2583602 T3 ES2583602 T3 ES 2583602T3 ES 08761564 T ES08761564 T ES 08761564T ES 2583602 T3 ES2583602 T3 ES 2583602T3
- Authority
- ES
- Spain
- Prior art keywords
- mixture
- carbohydrates
- feeding
- product intended
- oral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract description 14
- 150000001720 carbohydrates Chemical class 0.000 title abstract description 10
- 235000014633 carbohydrates Nutrition 0.000 title abstract description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract description 7
- 229920002774 Maltodextrin Polymers 0.000 abstract description 3
- 239000005913 Maltodextrin Substances 0.000 abstract description 3
- 229940035034 maltodextrin Drugs 0.000 abstract description 3
- 206010012601 diabetes mellitus Diseases 0.000 abstract 2
- 229930091371 Fructose Natural products 0.000 abstract 1
- 239000005715 Fructose Substances 0.000 abstract 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- 229920000294 Resistant starch Polymers 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 235000013305 food Nutrition 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- 235000021254 resistant starch Nutrition 0.000 abstract 1
- 239000008103 glucose Substances 0.000 description 6
- 239000000654 additive Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 108010005636 polypeptide C Proteins 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 235000014755 Eruca sativa Nutrition 0.000 description 1
- 244000024675 Eruca sativa Species 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 239000000619 acesulfame-K Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000013065 commercial product Substances 0.000 description 1
- FYGDTMLNYKFZSV-MRCIVHHJSA-N dextrin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)OC1O[C@@H]1[C@@H](CO)OC(O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-MRCIVHHJSA-N 0.000 description 1
- 230000002641 glycemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
- A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
- A23L29/212—Starch; Modified starch; Starch derivatives, e.g. esters or ethers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/30—Foods or foodstuffs containing additives; Preparation or treatment thereof containing carbohydrate syrups; containing sugars; containing sugar alcohols, e.g. xylitol; containing starch hydrolysates, e.g. dextrin
- A23L29/35—Degradation products of starch, e.g. hydrolysates, dextrins; Enzymatically modified starches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Endocrinology (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pediatric Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una nueva mezcla de hidratos de carbono y a su utilización para la preparación de un producto alimenticio destinado a la alimentación vía oral o enteral, en especial para la alimentación del paciente diabético y en particularpara la alimentación del paciente de diabetes de tipo Il y su comorbilidad asociada. La mezcla de hidratos de carbono de Ia presente invención está constituida por almidón resistente de tipo IVo RS IV (maltodextrina modificada), maltodextrina de baja dextrosa equivalente DE = 5-8, preferentemente DE igual a 6, inulina y celulosa y está exenta de fructosa.
Description
En una forma de realización de la invención, la mezcla de hidratos de carbono de la presente invención contiene además un aditivo edulcorante, preferentemente acesulfame potásico, y/o un estabilizante, preferentemente carragenato I. Preferentemente, la proporción de estos aditivos presente en la mezcla es del 0,32% para el edulcorante y del 0,22% para el estabilizante, porcentajes con respecto a la cantidad total de mezcla.
La maltodextrina modificada o almidón resistente de tipo IV, que constituye el 50,98% de los hidratos de carbono presentes en la mezcla de la invención, se incorpora a la mezcla de hidratos de carbono de la invención en forma del producto comercial Nutriose® FM06, de la firma Roquette.
Descripción de las figuras:
- Figura 1:
- curva correspondiente al índice glucémico obtenido con la mezcla de
- hidratos de carbono de la invención en comparación con un patrón de
- glucosa según un ejemplo de realización.
- Figura 2:
- curva correspondiente a la respuesta insulínica obtenida con la
- mezcla de hidratos de carbono de la invención en comparación con
- un patrón de glucosa según un ejemplo de realización.
- Figura 3:
- curva correspondiente al péptido C obtenida con la mezcla de hidratos
- de carbono de la invención en comparación con un patrón de glucosa
- según un ejemplo de realización.
- Figura 4:
- curva correspondiente al nivel de triglicéridos obtenida con la mezcla
- de hidratos de carbono de la invención en comparación con un patrón
- de glucosa según un ejemplo de realización.
En un ejemplo de realización, la mezcla de hidratos de carbono de la invención está constituida por los ingredientes y las cantidades de los mismos mostrados en la siguiente Tabla 1:
Tabla 1
-9
- Mezcla de HC
- 50 g de
- según la invención
- glucosa
- Tiempo (min)
- Media SEM Media SEM
- Glucosa
- 0 87,5 2,4 88,1 3,4
- 15
- 104,5 4,2 109,8 5,8
- 30
- 131,5 5,5 140,4 7,6
- 45
- 138,0 7,5 154,0 9,7
- 60
- 125,0 7,9 140,6 11,0
- 90
- 94,1 6,3 107,1 8,2
- 120
- 78,7 2,0 81,9 7,6
- 180
- 75,6 2,0 70,4 1,9
- Insulina
- 0 9,2 1,4 8,2 1,6
- 15
- 20,0 2,8 25,4 4,5
- 30
- 32,4 4,7 55,3 7,7
- 45
- 36,4 6,0 56,4 9,3
- 60
- 29,4 5,2 67,3 13,7
- 90
- 16,3 4,0 46,4 9,6
- 120
- 10,3 2,0 27,1 6,7
- 180
- 7,4 1,3 8,4 1,7
- Péptido C
- 0 2,4 0,4 2,4 0,3
- 15
- 3,4 0,4 3,9 0,5
- 30
- 5,1 0,6 6,5 0,6
- 45
- 5,9 0,7 7,9 0,7
- 60
- 5,7 0,7 9,1 0,9
- 90
- 4,5 0,6 8,2 0,8
- 120
- 3,3 0,5 6,1 0,8
- 180
- 2,4 0,4 2,9 0,4
- TAG
- 0 112,5 19,6 111,6 20,6
- 15
- 101,2 17,1 103,3 18,4
- 30
- 107,4 17,2 104,8 16,4
- 45
- 104,0 16,0 107,5 16,0
- 60
- 98,8 15,9 106,8 17,4
- 90
- 92,9 14,8 102,8 18,3
- 120
- 85,5 13,6 94,0 18,1
- 180
- 83,3 12,9 93,1 18,3
TAG = Triacilglicéridos
-11
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/ES2008/000319 WO2009135960A1 (es) | 2008-05-07 | 2008-05-07 | Mezcla de hidratos de carbono y su utilización para preparar un producto destinado a la alimentación oral o enteral |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2583602T3 true ES2583602T3 (es) | 2016-09-21 |
Family
ID=41264457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08761564.7T Active ES2583602T3 (es) | 2008-05-07 | 2008-05-07 | Mezcla de hidratos de carbono y su utilización para preparar un producto destinado a la alimentación oral o enteral |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110053888A1 (es) |
| EP (1) | EP2294932B1 (es) |
| CL (1) | CL2009001087A1 (es) |
| ES (1) | ES2583602T3 (es) |
| PT (1) | PT2294932E (es) |
| WO (1) | WO2009135960A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6104647B2 (ja) * | 2013-03-07 | 2017-03-29 | 三栄源エフ・エフ・アイ株式会社 | 半固形化流動食又は栄養剤 |
| CZ306430B6 (cs) * | 2015-08-20 | 2017-01-18 | Vysoká škola chemicko-technologická v Praze | Kompozice s vyšším obsahem rezistentního škrobu na bázi chemické a extruzní modifikace škrobu |
| CN111084384A (zh) * | 2019-12-30 | 2020-05-01 | 湖南点道生物科技有限公司 | 一种复合碳水化合物组件及其制备方法 |
| US11549133B2 (en) * | 2020-01-17 | 2023-01-10 | Jiangnan University | Preparation method of amylodextrin |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5358729A (en) * | 1991-08-28 | 1994-10-25 | Matsutani Chemical Industries Co., Ltd. | Indigestible dextrin |
| NZ250048A (en) * | 1992-10-28 | 1994-10-26 | Enzyme Bio Systems Ltd | Production of maltodextrins by selective hydrolysation of starches by enzymatic methods |
| DE69506095T2 (de) * | 1995-08-04 | 1999-06-24 | Naamloze Vennootschap Nutricia, Zoetermeer | Diätfasern enthaltende Nahrungszusammensetzung |
| MY115050A (en) * | 1995-10-16 | 2003-03-31 | Mead Johnson Nutrition Co | Diabetic nutritional product having controlled absorption of carbohydrate |
| DE69818594T2 (de) | 1997-06-23 | 2004-09-23 | Société des Produits Nestlé S.A. | Verwendung einer nutritiven Zusammensetzung zur Herstellung einer flüssigen Zusammensetzung für Diabetiker |
| DE10214327A1 (de) | 2001-10-23 | 2003-05-22 | Innogel Ag Zug | Netzwerk auf Polysaccharidbasis und Verfahren zu dessen Herstellung |
| US20040087514A1 (en) * | 2002-09-06 | 2004-05-06 | Hughes Thomas E | Nutritional compositions |
| AU2004281184C1 (en) * | 2003-10-16 | 2012-01-12 | Techcom Group, Llc | Reduced digestible carbohydrate food having reduced blood glucose response |
| SE0400355D0 (sv) | 2004-02-17 | 2004-02-17 | Synbiotics Ab | New synbiotec use |
| US20060025381A1 (en) * | 2004-07-29 | 2006-02-02 | National Starch And Chemical Investment Holding Company | Use of a chemically modified starch product |
| US20060068073A1 (en) | 2004-09-28 | 2006-03-30 | Catani Steven J | Low calorie, palatable sugar substitute with water insoluble bulking agent |
| US20060093720A1 (en) | 2004-10-28 | 2006-05-04 | Ed Tatz | Pumpable, semi-solid low calorie sugar substitute compositions |
| AU2006231557B2 (en) * | 2005-04-06 | 2010-09-09 | Société des Produits Nestlé S.A. | A method and composition for nutritionally improving glucose control and insulin action |
| US7956031B2 (en) | 2005-05-31 | 2011-06-07 | Naidu Lp | Metallo-lactoferrin-coenzyme compositions for trigger and release of bioenergy |
| EP1898929A2 (en) | 2005-07-05 | 2008-03-19 | N.V. Nutricia | A carbohydrate fraction and use thereof for a flat postprandial glucose response |
| CA2629014A1 (en) * | 2005-12-13 | 2007-06-21 | Archer-Daniels-Midland Company | Food products, methods of producing thes food products, and methods of distributing the food products and ingredients thereof |
-
2008
- 2008-05-07 WO PCT/ES2008/000319 patent/WO2009135960A1/es active Application Filing
- 2008-05-07 US US12/990,930 patent/US20110053888A1/en not_active Abandoned
- 2008-05-07 EP EP08761564.7A patent/EP2294932B1/en not_active Revoked
- 2008-05-07 ES ES08761564.7T patent/ES2583602T3/es active Active
- 2008-05-07 PT PT87615647T patent/PT2294932E/pt unknown
-
2009
- 2009-05-06 CL CL2009001087A patent/CL2009001087A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2294932B1 (en) | 2015-10-21 |
| US20110053888A1 (en) | 2011-03-03 |
| EP2294932A1 (en) | 2011-03-16 |
| CL2009001087A1 (es) | 2010-10-01 |
| PT2294932E (pt) | 2016-02-03 |
| WO2009135960A1 (es) | 2009-11-12 |
| EP2294932A4 (en) | 2014-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Salvatore et al. | The diabetic cardiomyopathy: the contributing pathophysiological mechanisms | |
| Cetrullo et al. | mTOR, AMPK, and Sirt1: key players in metabolic stress management | |
| ES2583602T3 (es) | Mezcla de hidratos de carbono y su utilización para preparar un producto destinado a la alimentación oral o enteral | |
| RU2413428C2 (ru) | Углеводная композиция для равномерной реакции на глюкозу | |
| BRPI0821005A8 (pt) | Método para aumentar a eficiência da absorção de xantofilas e composição | |
| BR112013017314A2 (pt) | composições compreendendo inibidores de cotransportadores 1 e 2 de sódio-glicose e métodos de usos | |
| BR112012022104A2 (pt) | produtos e métodos para alimentos recheados, salgados, estáveis em prateleira. | |
| JP2012528830A5 (es) | ||
| PT2576524T (pt) | Resumo | |
| BR112012024379A2 (pt) | "peptídeos glucagon, seu uso, bem como composição farmacêutica" | |
| MX2016006577A (es) | Uso de composiciones nutritivas que tienen una cantidad baja de proteina. | |
| AR070869A1 (es) | Acidos dicarboxilicos de cadena media, sus derivados para tratar desordenes metabolicos | |
| NO20085374L (no) | Anvendelse av fytat som middel for a inhibere opplosning av krystaller av kalsiumsalter for forhindring av osteoporose | |
| BR112013030729A2 (pt) | preparação de carnalita e usos da mesma em aplicações comestíveis | |
| WO2010081204A2 (en) | Activators of the autophagic pathway | |
| ES2937282T3 (es) | Composiciones y métodos de uso del beta-hidroxi-beta-metilbutirato (HMB) para disminuir la masa grasa | |
| BR112015017109A2 (pt) | confeito de gelatina não cariogênico | |
| Ravingerová et al. | Upregulation of genes involved in cardiac metabolism enhances myocardial resistance to ischemia/reperfusion in the rat heart. | |
| RU2015120261A (ru) | Пищевая композиция для усиления чувства насыщения | |
| Burlina et al. | The potential role of gut microbiota and its modulators in the management of propionic and methylmalonic acidemia | |
| ES2262455B1 (es) | Bebida. | |
| BRPI0607558A2 (pt) | derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt) | |
| BR112013002176A2 (pt) | recheio de gorgura com gordura vegetal e adoçante | |
| Prashanth et al. | The beneficial effect of Coenzyme Q in diabetic neuropathy: An overview | |
| Rodop et al. | Mitochondrial dysfunction in aging and disease: The role of nutrition |